The Cancer Cell Signaling Program (SIG) is comprised of invesfigators dedicated to providing fundamental knowledge of the intra- and inter-cellular signaling pathways that control tumor cell proliferafion, migrafion, and survival and to understanding how this informafion can be used to improve the diagnosis, prevention, and treatment of cancer. Program members utilize this fundamental knowledge to study tumor cell responses to the microenvironment and to drug treatments, using in vitro cell culture models and in vivo genetically engineered mouse models and xenograft models of individual cancers. Studying cell signaling in the context of pre-clinical cancer models provides relevant translation of cell signaling to the practical context of therapeutic intervention. SIG is led by David Brautigan, PhD and J. Thomas Parsons, PhD both of whom have extensive experience in cell signaling research and programmatic and administrative leadership. The Program leaders catalyze advances in signaling research by organizing retreats to foster new and innovative approaches, dispense "mini" pilot grants to stimulate the development of new ideas and technologies with an emphasis on using Cancer Center Shared Resources, and contribute to the overall intellectual environment of the Cancer Center by participating in seminars, journal clubs, research in progress and graduate and postgraduate education. The research of the 22 members of SIG is organized around three themes: (1) understanding fundamental properties of cancer cell signaling networks;(2) identifying pathways that govern cell responses to the microenvironment;and (3) defining in vivo systems to study signaling networks and test preclinical therapeufic strategies for cancer treatment. Total extramural funding for the Program exceeds $18 million, including $2.5 million from the Nafional Cancer Institute (NCI). Over the past five years, SIG Members have published 504 Program-relevant papers of which 33% were inter-Programmatic and 13% were intra Programmatic. The future goals of SIG are to foster discovery science focused on the complex integrafion of signaling networks, on how tumors respond to the microenvironment, and how tumors evolve to survive anti cancer therapies. SIG will confinue to utilize the outstanding Shared Resources and promote collaboration and innovation. Finally, SIG will engage oncologists and surgeons within the program and Cancer Center to seize opportunities for translation of information on signaling networks to clinical applications.
The Cancer Cell Signaling Program studies the regulatory networks that control communication inside cells and between cells, and the ways these become deranged in cancer. Most molecularly targeted cancer therapies exploit this knowledge, and this Program over the past decade has made discoveries that have shaped the landscape of cancer treatment.
|Meisner, Joshua K; Annex, Brian H; Price, Richard J (2015) Despite normal arteriogenic and angiogenic responses, hind limb perfusion recovery and necrotic and fibroadipose tissue clearance are impaired in matrix metalloproteinase 9-deficient mice. J Vasc Surg 61:1583-94.e1-10|
|Zarling, Angela L; Obeng, Rebecca C; Desch, A Nicole et al. (2014) MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Res 74:6784-95|
|Henretta, Melissa S; Copeland, Amy R; Kelley, Sarah L et al. (2014) Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high risk patients. Gynecol Oncol 133:73-7|
|Jones, Ryan; Libby, Bruce; Showalter, Shayna L et al. (2014) Dosimetric comparison of (192)Ir high-dose-rate brachytherapy vs. 50 kV x-rays as techniques for breast intraoperative radiation therapy: conceptual development of image-guided intraoperative brachytherapy using a multilumen balloon applicator and in-room Brachytherapy 13:502-7|
|Santen, Richard J (2014) Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 142:52-61|
|Wang, Shaolin; Yang, Zhongli; Ma, Jennie Z et al. (2014) Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants. Mol Neurobiol 49:601-14|
|Cohen, Jarish N; Tewalt, Eric F; Rouhani, Sherin J et al. (2014) Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment. PLoS One 9:e87740|
|Newhook, Timothy E; Blais, Edik M; Lindberg, James M et al. (2014) A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One 9:e105631|
|Hubbard, Matthew A; Khalil, Ashraf A; Schoeff, Stephen S et al. (2014) Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model. Otolaryngol Head Neck Surg 151:92-99|
|Wang, Chun-Chao; Janes, Kevin A (2014) Non-genetic heterogeneity caused by differential single-cell adhesion. Cell Cycle 13:2149-50|
Showing the most recent 10 out of 187 publications